Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,403 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Benefit Clear all
Completed Phase 3 Interventional Results available

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease

NCT00529568
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
eltrombopag, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
59
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Oct 19, 2026, 5:34 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer

NCT02463032
View directory record Official record
Conditions
ER+ and AR+ Breast Cancer
Interventions
GTx-024
Drug
Lead sponsor
GTx
Industry
Eligibility
18 Years and older · Female only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
4
States / cities
Fort Lauderdale, Florida • Boston, Massachusetts • Billings, Montana + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 19, 2026, 5:34 PM EDT
Completed Phase 2 Interventional Results available

Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis

NCT01731951
View directory record Official record
Conditions
Primary Myelofibrosis, Secondary Myelofibrosis, Myeloid Malignancies
Interventions
Imetelstat
Drug
Lead sponsor
Geron Corporation
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Oct 19, 2026, 5:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase II Clinical Trial to Evaluate the Benefits of Postconditioning in ST-Elevation Myocardial Infarction (STEMI)

NCT01324453
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Post Conditioning + Primary PCI, Standard Primary PCI
Procedure
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
18 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 19, 2026, 5:34 PM EDT
Completed No phase listed Observational

Carolinas Cardiogenic Shock Initiative

NCT04985708
View directory record Official record
Conditions
Cardiogenic Shock, Acute; Myocardial Infarction, Complications
Interventions
data collection of clinically available procedures
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Oct 19, 2026, 5:34 PM EDT
Completed Phase 2 Interventional Results available

Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.

NCT01928576
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Epigenetic Therapy
Interventions
Azacitidine, Entinostat, Nivolumab, CC-486 300
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 19, 2026, 5:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Assessing the Impact of myHealth Rewards Program-related Communications on Enrollment: Replication

NCT04289623
View directory record Official record
Conditions
Health Promotion, Wellness Program
Interventions
Email, Loss frame, Testimonial (medical expert), Testimonial (rank-and-file), Social norms (percentage), Social norms (number)
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
13,546 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2021 · Synced Oct 19, 2026, 5:34 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

NCT03332797
View directory record Official record
Conditions
Breast Cancer
Interventions
GDC-9545, Palbociclib, LHRH Agonist
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
6
States / cities
Aurora, Colorado • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 19, 2026, 5:34 PM EDT
Completed Phase 1 Interventional Results available

A Phase 1 Study of LY2787106 in Cancer and Anemia

NCT01340976
View directory record Official record
Conditions
Anemia
Interventions
LY2787106, Iron Supplementation
Drug · Dietary Supplement
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
9
States / cities
La Jolla, California • Santa Monica, California • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 19, 2026, 5:34 PM EDT
Recruiting Not applicable Interventional

Assessing Patient Satisfaction and Confidence After Use of Educational Video to Augment Surgical Consent for Thyroid Surgery

NCT06918223
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Thyroid Informed Surgical Consent Augmenting Video (TISCAV), Standard Consent
Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 19, 2026, 5:34 PM EDT
Completed Phase 1 Interventional

Safety Study of MBP-426 (Liposomal Oxaliplatin Suspension for Injection) to Treat Advanced or Metastatic Solid Tumors

NCT00355888
View directory record Official record
Conditions
Cancer
Interventions
MBP-426
Drug
Lead sponsor
Mebiopharm Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 19, 2026, 5:34 PM EDT
Not listed Phase 4 Interventional

A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)

NCT03348618
View directory record Official record
Conditions
Pediatric Acute-Onset Neuropsychiatric Syndrome, Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections
Interventions
IVIG
Biological
Lead sponsor
IMMUNOe Research Centers
Industry
Eligibility
4 Years to 16 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Centennial, Colorado • Papillion, Nebraska • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 19, 2026, 5:34 PM EDT
Active, not recruiting Phase 2 Interventional Results available

PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia

NCT01589302
View directory record Official record
Conditions
Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory/Relapsed Chronic Lymphocytic Leukemia
Interventions
ibrutinib, Correlative laboratory samples, quality of life assessment
Drug · Other
Lead sponsor
Kami Maddocks, MD
Other
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 19, 2026, 5:34 PM EDT
Recruiting Phase 1Phase 2 Interventional

Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial

NCT06866262
View directory record Official record
Conditions
Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Inulin, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Questionnaire Administration
Procedure · Dietary Supplement · Biological + 1 more
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 19, 2026, 5:34 PM EDT
Recruiting Not applicable Interventional

myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

NCT05204888
View directory record Official record
Conditions
COPD
Interventions
myAirvo3, Pulse oximeter
Device
Lead sponsor
Temple University
Other
Eligibility
30 Years and older
Enrollment
642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
25
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 19, 2026, 5:34 PM EDT
Completed Not applicable Interventional

Testing the Effectiveness of Child and Parent-Targeted Health Promotion Interventions in Pediatric Stem Cell Transplantation

NCT00760227
View directory record Official record
Conditions
Bone Marrow, Stem Cell Transplant
Interventions
Massage Therapy, Humor Therapy, Relaxation Therapy
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Years to 18 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
3
States / cities
Columbus, Ohio • Philadelphia, Pennsylvania • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 29, 2011 · Synced Oct 19, 2026, 5:34 PM EDT
Completed Not applicable Interventional Results available

Self-Management Interventions for Chronic Pain Relief With Cancer Survivors

NCT03867760
View directory record Official record
Conditions
Chronic Pain
Interventions
Recorded Hypnosis Intervention, Recorded Relaxation Intervention
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 90 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Chicago, Illinois • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 19, 2026, 5:34 PM EDT
Completed Not applicable Interventional

A Randomized Controlled Trial of Meditation Compared to Exposure Therapy and Education Control on PTSD in Veterans

NCT01865123
View directory record Official record
Conditions
Post-traumatic Stress Disorder
Interventions
Transcendental Meditation, Prolonged Exposure, Educational control
Behavioral
Lead sponsor
United States Department of Defense
Federal
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2018 · Synced Oct 19, 2026, 5:34 PM EDT
Completed Not applicable Interventional

Benefits of Intrahospital Exercise Program in Pediatric HSCT

NCT06692478
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplant, Pediatric Cancer, Deconditioning
Interventions
Exercise regimen
Behavioral
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
4 Years to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 19, 2026, 5:34 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

SKY Breath Intervention

NCT05388110
View directory record Official record
Conditions
Depression, Anxiety Disorders
Interventions
SKY Breath Intervention
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
16 Years to 24 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 19, 2026, 5:34 PM EDT
Recruiting No phase listed Observational

The PREDICT Registry:

NCT03448926
View directory record Official record
Conditions
DCIS, Stage 0 Breast Cancer, Ductal Breast Carcinoma In Situ
Interventions
Treatment recommendation surveys, 7-gene biosignature
Other · Device
Lead sponsor
PreludeDx
Industry
Eligibility
30 Years to 85 Years · Female only
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
30
States / cities
Scottsdale, Arizona • La Jolla, California • San Mateo, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 19, 2026, 5:34 PM EDT
Completed Not applicable Interventional Results available

Continuous Glucose Monitoring (CGM) With a Low Carbohydrate Diet to Reduce Weight in Patients With Pre-Diabetes

NCT03695913
View directory record Official record
Conditions
Pre-diabetes
Interventions
Normal Diet, Low carb diet, CGM with no real time feedback, CGM with real time feedback), Education material
Other · Device · Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Livonia, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Oct 19, 2026, 5:34 PM EDT
Completed Not applicable Interventional

An Intervention to Promote Use of Smoking Cessation Resources Among Adults Using Community Food Pantries

NCT05273450
View directory record Official record
Conditions
Smoking Cessation, Food Insecurity
Interventions
Quitline Information with Reinforcement
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
21 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 19, 2026, 5:34 PM EDT
Completed Phase 2 Interventional

Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)

NCT01915589
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Refametinib (BAY86-9766)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Miami, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 19, 2026, 5:34 PM EDT